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1st Dept. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GermanySee Article, pages 876–882Autoimmune hepatitis (AIH) is more variable than other liver dis-
eases. Autoimmune hepatitis can present in young infants [1] and
in octogenarians [2]. AIH can be a slowly progressive smouldering
condition, or it can run an acute ﬂuctuating course characterized
by ﬂares and spontaneous apparent remission, albeit usually
associated with scarring and progressive ﬁbrosis. AIH can present
as a subclinical condition diagnosed on routine blood tests in an
asymptomatic person, and it can present as acute liver failure [3].
It is the acute and hyper-acute presentation of AIH that remains
the greatest challenge in this disease and at the same time has
the least evidence basis to guide diagnosis and management.
Key issues are the deﬁnition of diagnostic criteria, the need for
prognostic parameters, and the therapeutic approach to acute
AIH.
The report by the King’s College group in this issue of the Jour-
nal [4] summarizing their experience in a series of 32 patients
with acute severe AIH is thus an important attempt to answer
some of these questions. This study only looks at patients with
a severe impairment of liver function using an international nor-
malized ratio (INR) of >1.5 as their cut-off, a limit also used as the
cut-off for acute liver failure in the large American Acute Liver
Failure (ALF) study group [5]. This deﬁnition is helpful to allow
some comparison between the King’s data and the report of the
ALF consortium looking at features of autoimmunity in patients
presenting with cryptogenic acute liver failure, and it is the main
reason why it was used in the study. This INR deﬁnition of liver
failure does, however, have an important limitation: patients
were included, if at ‘‘any time during the index presentation’’
their INR was >1.5. As jaundice leads to vitamin K deﬁciency
through lack of resorption of this fat-soluble vitamin, substitution
of vitamin K is the ﬁrst measure undertaken in any patient with
jaundice and elevated INR, and only those patients remaining
above a limit of 1.5 can truly be considered to suffer from liver
failure. On the other hand, many patients with very severe acute
AIH may still have sufﬁcient hepatic reserve to provide adequate
levels of coagulation factors despite severe hepatic inﬂammationJournal of Hepatology 20
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be the best standard test for liver failure, it is not the best
parameter to measure severity of AIH, for which the degree of
necro-inﬂammation, measured by transaminase levels and/or
measured by histological criteria is likely to better reﬂect the
severity of the auto-aggressive condition [6].
The major challenge in acute severe AIH is to actually make
the correct diagnosis and to differentiate this condition from
other causes of acute liver disease. Diagnostic criteria of autoim-
mune hepatitis are largely based on the experience and data in
patients presenting with milder disease [7,8], and it appears that
both the more comprehensive 1999 revised diagnostic criteria of
the International Autoimmune Hepatitis Group (IAIHG) as well as
the simpliﬁed diagnostic criteria (SDC) have limitations in partic-
ular in this group of acute severe disease. In the present study,
the 1999 criteria were used as gold standard and only patients
fulﬁlling these criteria were included – thus we are unable to
judge if there might have been patients with acute severe AIH
overlooked by these criteria. The ALF study group in 2011 took
another approach [3]: all patients with ALF not explained by acet-
aminophen poisoning or viral hepatitis and in whom histology
was available, were studied, and characteristic features of auto-
immunity were looked at. This study showed convincingly that
many of these patients have both histological and serological evi-
dence of AIH, and the authors found a good correlation between
histological criteria and the simpliﬁed diagnostic criteria. Com-
parison of the patients between the two studies shows that the
King’s group has 91% women compared to 58% in the ALF study
– a difference likely due to the inclusion criteria used: as female
sex is included as one of the criteria in the 1999 IAIHG diagnostic
criteria, men with AIH are more likely to be missed out.
Both studies show that the most characteristic difference
between acute severe AIH and other forms of AIH is the distribu-
tion of necro-inﬂammation in the liver lobule: while periportal
inﬂammation with interface hepatitis is typical for most patients
with AIH, acute severe AIH often shows predominantly and
sometimes even exclusively centrilobular necrosis. This histolog-
ical feature was traditionally considered a typical feature of drug-
induced toxic liver injury, but these studies as well as earlier
reports clearly show that the same feature can be seen in very
acute AIH [9,10]. This is a very important message, as patholo-
gists and clinicians are likely to have overlooked many cases of
acute severe AIH simply because centrilobular necrosis was14 vol. 61 j 727–729
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erroneously interpreted as a clear evidence of toxic liver injury.
Especially in older patients, who are likely to have had exposure
to various drugs the diagnosis of acute severe AIH can thus be
easily overlooked, and possibly beneﬁcial immunosuppressive
therapy is missed out. In older men, acute AIH is particularly
likely to be misinterpreted, because treating physicians errone-
ously regard this disease as a disease of younger women.
In addition to histomorphological criteria that appear to be
clearly different in very acute AIH compared to more chronic
AIH, serological and laboratory features are also somewhat differ-
ent, and need to be better deﬁned. While both autoantibodies and
elevated IgG levels are very characteristic for AIH and present in
more than 90% of all chronically affected patients [11], both fea-
tures may be missing early in the course of patients with very
acute presentation. This may simply be due to the kinetics of
antibody production and clearance: in very acute disease,
patients may not have had time to accumulate IgG and autoanti-
bodies in their serum. Antibodies have a relatively long serum
half-life, and thus changes tend to be slower, both upward and
downward. The very wide range of normal IgG levels and the
presence of low-level autoantibodies in healthy persons as well
as other liver diseases make it difﬁcult to really distinguish AIH
from other causes of acute liver failure in patients with very
recent disease onset. It is not uncommon that only as time goes
on the more characteristic features become obvious, and their
response to treatment conﬁrms the diagnosis.
What is the beneﬁt of steroid treatment in these patients with
acute severe AIH? Unfortunately, despite the careful analysis
undertaken in this case series, we do not really know. Only 23
out of the 32 patients in this series received steroid therapy,
and there were differences between these groups initially making
the comparison almost impossible. Untreated patients showed
signiﬁcantly higher MELD scores, which might have been the
main reason for not giving these patients steroid treatment. All
untreated patients required liver transplantation, while of those
given steroid treatment, 13 responded to treatment and recov-
ered without liver transplantation. Of the 10 patients given ste-
roids and showing treatment failure, all required and reached
liver transplant. However, 4/10 died at various time-points
post-transplant, as did 2/9 patients transplanted without prior
steroid treatment. These results are too limited to justify treat-
ment recommendations, but they hint towards early treatment,
as a good response may make transplant unnecessary. Further-
more, prednisolone doses given in this study might have been
too low, as none of the patients received more than 40 mg orally
per day. In our experience 100 mg prednisolone intravenously is
required in acute severe AIH, but we have to admit, there are no
systematic data for this recommendation either. Nonetheless, in
paediatric AIH, in which very acute presentation is observed
more commonly, prednisolone doses are usually chosen at or
above 1 mg/kg body weight [12]. Therefore, we need the data
from other centres and need to compare the results of different
treatment approaches.
Discussion on the peculiar histological features of AIH may aid
in making the diagnosis in future patients. This will be an impor-
tant basis for the decision to biopsy early in acute liver failure. In
particular in patients with impaired INR clinicians are often hes-
itant to perform a liver biopsy, even though it is not clear if
changes in plasmatic coagulation parameters really increase the
risk of post-biopsy bleeding. Anti-coagulant factors are similarly
decreased in these patients as are the pro-coagulant factors728 Journal of Hepatology 201measured by INR. We lack studies, giving us clear guidance on
the value of early liver biopsy in acute liver failure. Future studies
addressing this issue, including the issue of safety and technique
(percutaneous [13], transjugular [14] or mini-laparoscopic biopsy
[15]), urgently need to be performed. The faster the diagnosis is
made, the earlier potentially effective treatment can be started.
It is likely that the beneﬁt of steroid treatment in acute severe
AIH might be decisively improved by earlier diagnosis and thus
earlier start of therapy. The other issue in steroid treatment of
acute severe AIH is the duration of high dose steroid therapy. In
the present study, no patient was lost prior to transplantation,
but that may have been due to early decisions to transplant.
The same group of investigators have published in 2011 that fail-
ure of a response to steroids after 7 days should be the cut-off
point to stop steroids and precede with transplantation [16]. Sim-
ilar results have been reported by others, albeit all in very small
case series [17]. In view of the signiﬁcant mortality post-trans-
plant and no mortality pre-transplant in the present report, we
may have rushed in this critical patient population with our
transplant decisions, and maybe more patients might achieve a
steroid-induced remission with perhaps higher initial doses, as
suggested above, and a little longer careful clinical observation.
What are the lessons for the general hepatologist? First, AIH
has to be considered early in any patient with very acute and
severe liver failure. Secondly, liver biopsy in acute liver failure
can be very helpful. However, features hitherto regarded as typ-
ical for drug-induced liver failure may also be seen in patients
with very acute AIH, and therefore the diagnosis of AIH should
not be discarded because of the presence of centrilobular necro-
sis. Thirdly, elevated IgG levels and autoantibodies can support
the suspected diagnosis of AIH, but may also be absent or non-
characteristic in very acute AIH. Fourthly, a trial of steroid ther-
apy in sufﬁciently high doses should be initiated very early, but
the risk of infections in liver failure needs to be kept in mind.
Finally, liver transplantation needs to be considered as an alter-
native, but nobody knows the best timing. In addition to these
clinical lessons, the scientiﬁc community still has considerable
homework to do, in order to deﬁne better the diagnostic criteria
and the best treatment algorithms for patients with acute severe
AIH. Due to the relative rarity of this condition, controlled trials
will not be feasible. Instead, data need to be collected from vari-
ous centres, and different approaches need to be compared. A
mortality rate of 27% even in an expert centre as in this study
shows that there is still plenty of room for improvement for these
patients.Conﬂict of interest
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